JSPR
Jasper TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The primary-source record supports constructive clinical positioning for briquilimab in CSU, with management highlighting positive January data, dose selection progress, and protocol refiling ahead of a planned Phase 2b study [#SEC-8K-2026-05-14].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
As a low-coverage micro-cap biotech, Jasper faces elevated volatility and thin external validation if milestones slip or financing terms are punitive.
Momentum
61
Value
41
Sentiment
2
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.45 · Bull $0.90 · Bear $0.20
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-14 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $8.17
Why
Momentum61 · Δ7d -
Value41 · Δ7d -0.1
Sentiment2 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
61
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-17.6
Sentiment
2
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 61.3 / Value 41.1 / Sentiment 1.9
Fundamentals (TTM)As of 2026-07-14
Fundamentals (TTM)
As of 2026-07-14
Market Cap
$20.25M
Beta
3.09
Shares Out
28.01M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.22
Rev YoY
-
EPS YoY
-97.1%
Gross Margin
-
Op Margin
-
Net Debt
-$27.46M
Current Ratio
2.26
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology